Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04730193 · ClinicalTrials.gov registry record · Early Phase 1

Caffeine and Cerebrovascular Reactivity

A Early Phase 1 study of Caffeine, sponsored by University of Oklahoma.

Completed
Registry status
Early Phase 1
Development phase
10
Enrollment target
1
Study location

NCT04730193 is a Early Phase 1 study of Caffeine that has completed, run by University of Oklahoma. The registered enrollment target is 10 participants, below the 74-participant average among 6 other Caffeine trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04730193, a Early Phase 1 study of Caffeine, has completed, sponsored by University of Oklahoma.

COMPLETED
Registry status
Early Phase 1
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

Caffeine is the most commonly used stimulant drug with well documented effects on cerebral vascula-ture. Caffeine is known to non-specifically bind to adenosine receptors in the brain and to reduce resting blood flow while improving attention and cognitive function, which suggests that it may allow a more efficient dynamic blood flow regulation through neurovascular coupling. This study will use standardized dose of caffeine to test its effect on NVC responses in cerebral and retinal arterioles.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Caffeine

Study Locations (1)

Oklahoma

  • Translational GeroScience Laboratory - Oklahoma City

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2021-02-01
Est. Completion 2022-08-01
Phase Early Phase 1

Sponsor

University of Oklahoma

358 total trials

What the Registry Record Tells You About NCT04730193

The ClinicalTrials.gov registry entry for NCT04730193 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 74-participant average among 6 other Caffeine trials with a reported enrollment target (86% lower). The listed sponsor is University of Oklahoma, which has 358 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Caffeine appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04730193 reports 1 study location spanning 1 distinct geographic area - top geographies include Oklahoma.

Frequently Asked Questions

What is clinical trial NCT04730193 about?

NCT04730193 is a clinical study titled "Caffeine and Cerebrovascular Reactivity". Caffeine is the most commonly used stimulant drug with well documented effects on cerebral vascula-ture. Caffeine is known to non-specifically bind to adenosine receptors in the brain and to reduce resting blood flow while improving attention and cognitive function, which suggests that it may allow ...

What is the current status of trial NCT04730193?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2021-02-01. Estimated completion is 2022-08-01.

What conditions does trial NCT04730193 study?

This clinical trial studies the following conditions: Caffeine.

What interventions are being tested in trial NCT04730193?

The interventions under investigation include: Placebo (DRUG), Caffeine (DRUG).

Who is sponsoring clinical trial NCT04730193?

This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04730193 being conducted?

This trial has 1 study location across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Caffeine

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.